ArticleCancers2021
Analysis of Telomere Maintenance Related Genes Reveals
Open access · goldAbstract read
In one paragraph
Article in Cancers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
1.9field-weighted citation impact, top 14% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 23 citations in OpenAlex.
- An Innovative Telomere-associated Prognosis Model in AML: Predicting Immune Infiltration and Treatment Responsiveness.Current medicinal chemistry · 2026Article
- The Molecular Classification of Pheochromocytomas and Paragangliomas: Discovering the Genomic and Immune Landscape of Metastatic Disease.Endocrine pathology · 2024Review
- Article
- Approach to the Patient: Concept and Application of Targeted Radiotherapy in the Paraganglioma Patient.The Journal of clinical endocrinology and metabolism · 2024Review
- Prediction of metastatic pheochromocytoma and paraganglioma: a machine learning modelling study using data from a cross-sectional cohort.The Lancet. Digital health · 2023Article
- Cytoplasmic HIF-2α as tissue biomarker to identify metastatic sympathetic paraganglioma.Scientific reports · 2023Article
- Genomic and immune landscape Of metastatic pheochromocytoma and paraganglioma.Nature communications · 2023Article
- Recurrent Disease in Patients With Sporadic Pheochromocytoma and Paraganglioma.The Journal of clinical endocrinology and metabolism · 2023Article
- Tumour microenvironment in pheochromocytoma and paraganglioma.Frontiers in endocrinology · 2023Review
- Clinical and Pathological Tools for Predicting Recurrence and/or Metastasis in Patients with Pheochromocytoma and Paraganglioma.Biomedicines · 2022Review
- Metformin Treatment Induces Different Response in Pheochromocytoma/Paraganglioma Tumour Cells and in Primary Fibroblasts.Cancers · 2022Article
- Article
- New Insights in the Genetics and Genomics of Adrenocortical Tumors and Pheochromocytomas.Cancers · 2022Article
- Mutational Profile and Potential Molecular Therapeutic Targets of Pheochromocytoma.Frontiers in endocrinology · 2022Article
- Case Report: Genetic Alterations Associated with the Progression of Carotid Paraganglioma.Current issues in molecular biology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
38 authors at 8 institutions in 4 countries.
María MonteagudoHereditary Endocrine Cancer Group, Human Cancer Genetics Program, Spanish National Cancer Research Centre (CNIO), 28029 Madrid, Spain.ORCID 0000-0002-6280-2987
Paula MartínezTelomeres and telomerase Group, Molecular Oncology Program, Spanish National Cancer Research Centre (CNIO), 28029 Madrid, Spain.
Luis J Leandro-GarcíaHereditary Endocrine Cancer Group, Human Cancer Genetics Program, Spanish National Cancer Research Centre (CNIO), 28029 Madrid, Spain.
Ángel M Martínez-MontesHereditary Endocrine Cancer Group, Human Cancer Genetics Program, Spanish National Cancer Research Centre (CNIO), 28029 Madrid, Spain.
Bruna CalsinaHereditary Endocrine Cancer Group, Human Cancer Genetics Program, Spanish National Cancer Research Centre (CNIO), 28029 Madrid, Spain.ORCID 0000-0002-6922-9415
Marta Pulgarín-AlfaroHereditary Endocrine Cancer Group, Human Cancer Genetics Program, Spanish National Cancer Research Centre (CNIO), 28029 Madrid, Spain.
Alberto Díaz-TalaveraHereditary Endocrine Cancer Group, Human Cancer Genetics Program, Spanish National Cancer Research Centre (CNIO), 28029 Madrid, Spain.ORCID 0000-0003-4279-338X
Sara MellidHereditary Endocrine Cancer Group, Human Cancer Genetics Program, Spanish National Cancer Research Centre (CNIO), 28029 Madrid, Spain.
Rocío LetónHereditary Endocrine Cancer Group, Human Cancer Genetics Program, Spanish National Cancer Research Centre (CNIO), 28029 Madrid, Spain.
Eduardo GilHereditary Endocrine Cancer Group, Human Cancer Genetics Program, Spanish National Cancer Research Centre (CNIO), 28029 Madrid, Spain.
Manuel Pérez-MartínezConfocal Microscopy Core Unit, Biotechnology Program, Spanish National Cancer Research Centre (CNIO), 28029 Madrid, Spain.
Diego MegíasConfocal Microscopy Core Unit, Biotechnology Program, Spanish National Cancer Research Centre (CNIO), 28029 Madrid, Spain.
Raúl Torres-RuizMolecular Citogenetic, Unit Human Cancer Genetics Program, Spanish National Cancer Research Centre (CNIO), 28029 Madrid, Spain.ORCID 0000-0001-9606-0398
Sandra Rodriguez-PeralesMolecular Citogenetic, Unit Human Cancer Genetics Program, Spanish National Cancer Research Centre (CNIO), 28029 Madrid, Spain.
Patricia GonzálezHistopathology Core Unit, Biotechnology Program, Spanish National Cancer Research Centre (CNIO), 28029 Madrid, Spain.
Eduardo CaleirasHistopathology Core Unit, Biotechnology Program, Spanish National Cancer Research Centre (CNIO), 28029 Madrid, Spain.ORCID 0000-0001-8768-3630
Scherezade Jiménez-VillaMonoclonal Antibodies Core Unit, Biotechnology Program, Spanish National Cancer Research Centre (CNIO), 28029 Madrid, Spain.
Giovanna RoncadorMonoclonal Antibodies Core Unit, Biotechnology Program, Spanish National Cancer Research Centre (CNIO), 28029 Madrid, Spain.
Cristina Álvarez-EscoláDepartment of Endocrinology, La Paz University Hospital, 28046 Madrid, Spain.
Rita M RegojoDepartment of Pathology La Paz University Hospital, 28046 Madrid, Spain.ORCID 0000-0001-9421-1455
María CalatayudDepartment of Endocrinology, 12 de Octubre University Hospital, 28041 Madrid, Spain.
Sonsoles GuadalixDepartment of Endocrinology, 12 de Octubre University Hospital, 28041 Madrid, Spain.
Maria Currás-FreixesDepartment of Endocrinology, Clínica Universidad de Navarra, 28027 Madrid, Spain.
Elena RapizziDepartment of Experimental and Clinical Medicine, University of Florence, 50121 Florence, Italy.ORCID 0000-0002-3826-2714
Letizia CanuDepartment of Experimental and Clinical Medicine, University of Florence, 50121 Florence, Italy.ORCID 0000-0003-4995-8108
Svenja NöltingMedizinische Klinik und Poliklinik IV, Klinikum der Universität München, 80336 Munich, Germany.
Hanna RemdeDepartment of Internal Medicine I, Division of Endocrinology and Diabetes, University Hospital Würzburg, University of Würzburg, 97070 Würzburg, Germany.
Martin FassnachtDepartment of Internal Medicine I, Division of Endocrinology and Diabetes, University Hospital Würzburg, University of Würzburg, 97070 Würzburg, Germany.ORCID 0000-0001-6170-6398
Nicole BechmannInstitute of Clinical Chemistry and Laboratory Medicine, University Hospital Carl Gustav Carus, Technische Universität Dresden, 01069 Dresden, Germany.ORCID 0000-0002-6932-333X
Graeme EisenhoferInstitute of Clinical Chemistry and Laboratory Medicine, University Hospital Carl Gustav Carus, Technische Universität Dresden, 01069 Dresden, Germany.
Massimo MannelliDepartment of Experimental and Clinical Medicine, University of Florence, 50121 Florence, Italy.
Felix BeuschleinMedizinische Klinik und Poliklinik IV, Klinikum der Universität München, 80336 Munich, Germany.
Marcus QuinklerEndocrinology in Charlottenburg Stuttgarter Platz 1, 10627 Berlin, Germany.
Cristina Rodríguez-AntonaHereditary Endocrine Cancer Group, Human Cancer Genetics Program, Spanish National Cancer Research Centre (CNIO), 28029 Madrid, Spain.
Alberto CascónHereditary Endocrine Cancer Group, Human Cancer Genetics Program, Spanish National Cancer Research Centre (CNIO), 28029 Madrid, Spain.ORCID 0000-0003-2119-891X
María A BlascoTelomeres and telomerase Group, Molecular Oncology Program, Spanish National Cancer Research Centre (CNIO), 28029 Madrid, Spain.
Cristina Montero-CondeHereditary Endocrine Cancer Group, Human Cancer Genetics Program, Spanish National Cancer Research Centre (CNIO), 28029 Madrid, Spain.ORCID 0000-0002-4452-4469
Mercedes RobledoHereditary Endocrine Cancer Group, Human Cancer Genetics Program, Spanish National Cancer Research Centre (CNIO), 28029 Madrid, Spain.
Spanish National Cancer Research Centre · ESUniversity of Florence · ITHospital Universitario La Paz · ESLMU Klinikum · DEResearch Institute Hospital 12 de Octubre · ESUniversity Hospital Carl Gustav Carus · DEUniversity of Würzburg · DEClinica Universidad de Navarra · ES
Funding
Centro de Investigacion Biomédica en Red de Enfermedades Raras no grant number applicableComunidad de Madrid S2017/BMD-3724; TIRONET2-CMComunidad de Madrid S2017/BMD-3770Deutsche Forschungsgemeinschaft (DFG) within the CRC/Transregio 205/1European Research Council ERC-AvG Shelterines GA882385Fundación Botín no grant number applicableFundación Científica Asociación Española Contra el Cáncer AIO15152858 MONTFundación Rafael del Pino Becas de Excelencia Rafael del Pino 2017Immuno-TargET project under the umbrella of University Medicine Zurich no grant number applicableInstituto de Salud Carlos III PI17/01796Instituto de Salud Carlos III (ISCIII), Acción Estratégica en Salud, cofinanciado a través del Fondo Europeo de Desarrollo Regional (FEDER) PI17/01796, PI20/01169"la Caixa" Foundation LCF/BQ/PI20/11760011Paradifference Foundation no grant number applicable to M.R.Pheipas Association no grant number applicable to M.R.Spanish Ministry of Science, Innovation and Universities FPU18/00064Spanish State Research Agency (AEI), Ministry of Science and Innovation, cofounded by the European Regional Development Fund (ERDF) SAF2017-82623-R, SAF2015-72455-EXPWorldwide Cancer Research 16-1177
Abstract
One of the main problems we face with PPGL is the lack of molecular markers capable of predicting the development of metastases in patients. Telomere-related genes, such as
Indexed as
ALTATRXNOP10paragangliomapheochromocytomaPPGLprognostic biomarkertelomeresTERT
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.